ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

Address

Zernikedreef 9

Website

https://www.proqr.com

Classification

Sector

Healthcare

Industry Group

Biotechnology

Industry

Biotechnology

Key Executives

Mr. Rene Beukema

General Counsel/Other Executive Officer

Dr. James S. Shannon, M.D.,M.R.C.P.

Director

Mr. Bart Filius, M.B.A.

Director

Ms. Alison F. Lawton

Director

Mr. Antoine Papiernik

Director

Mr. Dinko Valerio

Chairman of Supervisory Board/Director

Mr. Daniel de Boer

CEO/Co-Founder

Mr. Gerard Platenburg

Chief Scientific Officer/Co-Founder

Mr. Aniz Girach

Chief Medical Officer

Ms. Sheila Sponselee

Other Corporate Officer/Vice President

Mr. Jurriaan Dekkers

CFO

Ownership

Institution Holdings

Eli Lilly and Co

13,371,562 (16.476%)

Privium Fund Management B.V.

5,344,446 (6.585%)

Adage Capital Partners Gp LLC

3,625,467 (4.467%)

EcoR1 Capital, LLC

2,980,016 (3.672%)

M28 Capital Management LP

1,910,600 (2.354%)

Dafna Capital Management LLC

940,582 (1.159%)

De Grote Voskuil Capital BV

800,000 (0.986%)

Macquarie Group Ltd

620,000 (0.764%)

Macquarie Investment Management Aus Ltd.

620,000 (0.764%)

Delaware Management Company

620,000 (0.764%)

Details

Overview

Company Info

Key Ratios

Income

Balance Sheet

Cash Flow

Bubble

Make Smart Investment Choices